1. Home
  2. KD vs LEGN Comparison

KD vs LEGN Comparison

Compare KD & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kyndryl Holdings Inc.

KD

Kyndryl Holdings Inc.

HOLD

Current Price

$12.35

Market Cap

2.8B

Sector

Technology

ML Signal

HOLD

Logo Legend Biotech Corporation

LEGN

Legend Biotech Corporation

HOLD

Current Price

$18.76

Market Cap

5.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KD
LEGN
Founded
2020
2014
Country
United States
United States
Employees
80000
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
5.9B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
KD
LEGN
Price
$12.35
$18.76
Analyst Decision
Buy
Strong Buy
Analyst Count
5
13
Target Price
$35.25
$63.08
AVG Volume (30 Days)
4.7M
1.7M
Earning Date
05-11-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
170.95
N/A
EPS
0.77
N/A
Revenue
$15,057,000,000.00
N/A
Revenue This Year
$3.96
$46.27
Revenue Next Year
$0.41
$28.77
P/E Ratio
$16.31
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.10
$16.24
52 Week High
$43.74
$45.30

Technical Indicators

Market Signals
Indicator
KD
LEGN
Relative Strength Index (RSI) 33.95 49.02
Support Level $11.34 $17.46
Resistance Level $13.81 $23.68
Average True Range (ATR) 0.51 0.81
MACD 0.45 0.16
Stochastic Oscillator 42.98 47.10

Price Performance

Historical Comparison
KD
LEGN

About KD Kyndryl Holdings Inc.

Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives. The company's reportable segments consist of the following: Principal Markets which represents its operations in operations in Australia / New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, and the United Kingdom / Ireland, United States, Japan, and Strategic Markets. It derives maximum revenue from the United States.

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

Share on Social Networks: